Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial

Buckwalter, 2004, Sports and osteoarthritis, Curr Opin Rheumatol, 16, 634, 10.1097/01.bor.0000132647.55056.a9 Kim, 2007, Biomarkers of muscle and cartilage damage and inflammation during a 200 km run, Eur J Appl Physiol, 99, 443, 10.1007/s00421-006-0362-y Lequesne, 1997, Sport practice and osteoarthritis of the limbs, Osteoarthritis Cartilage, 5, 75, 10.1016/S1063-4584(97)80001-5 Neidhart, 2000, Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners, Osteoarthritis Cartilage, 8, 222, 10.1053/joca.1999.0293 Kivitz, 2002, Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis, J Fam Pract, 51, 530 Simon, 1998, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum, 41, 1591, 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J Borgdorff, 2006, Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation, J Am Coll Cardiol, 48, 817, 10.1016/j.jacc.2006.03.053 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Graham, 2005, Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study, Lancet, 365, 475, 10.1016/S0140-6736(05)70270-1 McGettigan, 2006, Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2, JAMA, 296, 1633, 10.1001/jama.296.13.jrv60011 Clegg, 2006, Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis, N Engl J Med, 354, 795, 10.1056/NEJMoa052771 Michel, 2005, Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial, Arthritis Rheum, 52, 779, 10.1002/art.20867 Uebelhart, 2004, Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo, Osteoarthritis Cartilage, 12, 269, 10.1016/j.joca.2004.01.004 Chan, 2005, Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants, Am J Vet Res, 66, 1870, 10.2460/ajvr.2005.66.1870 Abramson, 2002, Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage, Rheumatology (Oxford), 41, 972, 10.1093/rheumatology/41.9.972 Fernandes, 2002, The role of cytokines in osteoarthritis pathophysiology, Biorheology, 39, 237 Pelletier, 1995, Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process, J Rheumatol Suppl, 43, 109 Vuolteenaho, 2002, Effects of TNFalpha-antagonists on nitric oxide production in human cartilage, Osteoarthritis Cartilage, 10, 327, 10.1053/joca.2002.0521 Goldring, 1999, The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models, Connect Tissue Res, 40, 1, 10.3109/03008209909005273 Goldring, 2000, Osteoarthritis and cartilage: the role of cytokines, Curr Rheumatol Rep, 2, 459, 10.1007/s11926-000-0021-y Chambers, 1997, Chondrocyte cytokine and growth factor expression in murine osteoarthritis, Osteoarthritis Cartilage, 5, 301, 10.1016/S1063-4584(97)80034-9 Pelletier, 1993, Coordinate synthesis of stromelysin, interleukin-1, and oncogene proteins in experimental osteoarthritis. An immunohistochemical study, Am J Pathol, 142, 95 Verbruggen, 2006, Chondroprotective drugs in degenerative joint diseases, Rheumatology (Oxford), 45, 129, 10.1093/rheumatology/kei171 Arend, 1995, Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis, Arthritis Rheum, 38, 151, 10.1002/art.1780380202 Westacott, 1996, Cytokines in osteoarthritis: mediators or markers of joint destruction?, Semin Arthritis Rheum, 25, 254, 10.1016/S0049-0172(96)80036-9 Seckinger, 1990, An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells, Immunobiology, 180, 316, 10.1016/S0171-2985(11)80295-0 Frisbie, 2002, Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene, Gene Ther, 9, 12, 10.1038/sj.gt.3301608 Meijer, 2003, The production of anti-inflammatory cytokines in whole blood by physico-chemical induction, Inflamm Res, 52, 404, 10.1007/s00011-003-1197-1 Felson, 2000, Osteoarthritis: new insights. Part 1: the disease and its risk factors, Ann Intern Med, 133, 635, 10.7326/0003-4819-133-8-200010170-00016 Gupta, 2005, The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition, Rheumatology (Oxford), 44, 1531, 10.1093/rheumatology/kei049 Altman, 2004, Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee, Osteoarthritis Cartilage, 12, 642, 10.1016/j.joca.2004.04.010 Hughes, 2002, A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee, Rheumatology (Oxford), 41, 279, 10.1093/rheumatology/41.3.279 Pavelka, 2002, Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study, Arch Intern Med, 162, 2113, 10.1001/archinte.162.18.2113 Razmjou, 2006, Response shift in outcome assessment in patients undergoing total knee arthroplasty, J Bone Joint Surg Am,, 88, 2590, 10.2106/JBJS.F.00283 Ring, 2005, Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients, Health Qual Life Outcomes, 3, 55, 10.1186/1477-7525-3-55 Heilmann, 1996, [Synovial volume of healthy and arthrotic human knee joints], Z Orthop Ihre Grenzgeb, 134, 144, 10.1055/s-2008-1039786 Neidel, 1996, [Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis], Z Orthop Ihre Grenzgeb, 134, 381, 10.1055/s-2008-1039779 Granowitz, 1991, Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor, J Biol Chem, 266, 14147, 10.1016/S0021-9258(18)98655-2 Dinarello, 1991, Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro, Immunol Today, 12, 404, 10.1016/0167-5699(91)90142-G Smugar, 2006, Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies, Curr Med Res Opin, 22, 1353, 10.1185/030079906X104876 Mastbergen, 2005, Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study, Osteoarthritis Cartilage, 13, 519, 10.1016/j.joca.2005.02.004 Mastbergen, 2002, Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage, Rheumatology (Oxford), 41, 801, 10.1093/rheumatology/41.7.801 Rodrigo, 1995, Effects of human knee synovial fluid on chondrogenesis in vitro, Am J Knee Surg, 8, 124 Saris, 2003, Joint homeostasis: the discrepancy between old and fresh defects in cartilage repair, J Bone Joint Surg Br, 85-B, 1067, 10.1302/0301-620X.85B7.13745 Mankin, 1974, The reaction of articular cartilage to injury and osteoarthritis (first of two parts), N Engl J Med, 291, 1285, 10.1056/NEJM197412122912406 Mankin, 1974, The reaction of articular cartilage to injury and osteoarthritis (second of two parts), N Engl J Med, 291, 1335, 10.1056/NEJM197412192912507